Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Nasdaq Biotechnology

116.60
+0.20700.18%
Volume:10K
Turnover:1.13M
Market Cap:101.44M
PE:- -
High:116.74
Open:116.27
Low:113.31
Close:116.39
52wk High:126.40
52wk Low:55.34
Shares:870.00K
Float Shares:870.00K
Volume Ratio:0.88
T/O Rate:1.13%
Dividend:0.33
Dividend Rate:0.28%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Amgen Inc : Canaccord Genuity Raises Target Price to $384 from $366

THOMSON REUTERS
·
Aug 05

Immuneering Expects Cash Runway to Fund Operations into 2029

Reuters
·
Aug 05

Analysts Offer Insights on Healthcare Companies: Exagen (XGN), Amgen (AMGN) and Arvinas Holding Company (ARVN)

TIPRANKS
·
Aug 05

Kymera Therapeutics Q2 Collaboration Revenue More than Doubles, Beats Estimates

Reuters
·
Aug 05

Gilead : Leerink Partners Raises Target Price to $130 from $126

THOMSON REUTERS
·
Aug 05

Amgen Inc : Scotiabank Raises Target Price to $450 from $385

THOMSON REUTERS
·
Aug 05

Gilead Sciences (GILD) Gets a Buy from Wells Fargo

TIPRANKS
·
Aug 05

Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained

TIPRANKS
·
Aug 05

Street View: Gilead's HIV Strength Outshines Long-Term Competitive Worries

Reuters
·
Aug 05

Sino Biopharmaceutical Stock Slips 1.2% in Hong Kong

Dow Jones
·
Aug 05

Street View: Amgen Builds Momentum with Blockbusters, Biosimilars and a Pipeline in Waiting

Reuters
·
Aug 05

Amgen Inc : Morgan Stanley Raises Target Price to $351 from $333

THOMSON REUTERS
·
Aug 05

Switzerland's Sandoz H1 Net Sales Rise on Biosimilar Growth

Reuters
·
Aug 05

Amgen Inc : Oppenheimer Raises Target Price to $450 from $400

THOMSON REUTERS
·
Aug 05

Gilead : Truist Securities Cuts Target Price to $150 from $156

THOMSON REUTERS
·
Aug 05

Gilead Corrects Q2 2026 Europe Odefsey Sales to $58 Million

Reuters
·
Aug 05

Dow Jones Top Company Headlines at 7 PM ET: SpaceX Revenue Could Reach $1 Trillion, Elon Musk Says | Paramount's ...

Dow Jones
·
Aug 05

Gilead Forecasts FY26 Yeztugo Revenue at About $1 Billion

Reuters
·
Aug 05

Gilead CEO Daniel O’Day Sells 15,000 Common Shares Worth $1.96 Million

Reuters
·
Aug 05

Gilead Says Q2 2026 Revenue Growth is Driven by Biktarvy, Descovy and Yeztugo Demand, Pricing Gains

Reuters
·
Aug 05